Quick Answer
Skye Bioscience, Inc. reported Stockholders Equity of $20.02 million for the year ending 2025.
- Skye Bioscience, Inc. showed a decrease of -70.6% in Stockholders Equity from 2024 to 2025.
- This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.75 million | Q2 2018: -$8.25 million | Q3 2018: -$10.16 million | Q1 2019: -$27.86 million | Q2 2019: -$11.64 million | Q3 2019: -$16.40 million | Q1 2020: -$1.70 million | Q2 2020: -$3.09 million | Q3 2020: $1.85 million | Q1 2021: $2.48 million | Q2 2021: $2.27 million | Q3 2021: $8.26 million | Q1 2022: $2.97 million | Q2 2022: -$301.8 thousand | Q3 2022: -$3.28 million | Q1 2023: -$4.78 million | Q2 2023: -$7.79 million | Q3 2023: $1.70 million | Q1 2024: $78.88 million | Q2 2024: $72.81 million | Q3 2024: $75.80 million | Q1 2025: $59.25 million | Q2 2025: $43.68 million | Q3 2025: $32.84 million.
- Over the full 17 years of available data (2011 to 2025), Skye Bioscience, Inc.'s Stockholders Equity has grown by 77,064.5%.
- Historical annual values: Fiscal year 2025: $20.02 million | Fiscal year 2024: $68.15 million | Fiscal year 2023: -$2.13 million | Fiscal year 2022: -$3.01 million | Fiscal year 2021: $5.86 million | Fiscal year 2020: $450.8 thousand | Fiscal year 2019: $548.1 thousand | Fiscal year 2018: -$15.56 million | Fiscal year 2017: -$3.57 million | Fiscal year 2016: -$2.91 million | Fiscal year 2015: -$892.2 thousand | Fiscal year 2014: -$453.5 thousand | Fiscal year 2013: -$182.2 thousand | Fiscal year 2013: $83.4 thousand | Fiscal year 2012: -$61.8 thousand | Fiscal year 2012: $38.6 thousand | Fiscal year 2011: $26.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: